Big effect
In a meta-analysis of 424 hospitalized COVID-19 patients, NAC was tied to a 51% lower odds of death — but the results varied considerably across the 10 small trials.
This is a large effect from a moderately strong body of evidence (4 of 7 studies show benefit, none show harm), but the small total sample and moderate statistical heterogeneity mean the precise size of the benefit is still uncertain.
Researchers pooled 10 randomized trials and found that patients given N-acetylcysteine had roughly half the odds of dying compared to those who did not receive it. However, the trials were small and their results differed from one another, so the true effect could be smaller or larger. Because the studies were done in a clinical COVID-19 setting, the finding may not apply to healthy people using NAC for general prevention.
Where this fits in the evidence
Pillser has synthesized 7 studies on N-Acetyl Cysteine for Reduced Mortality Risk — overall evidence strength: Moderate.
Across 7 studies, 4 reported beneficial effects of N-acetyl cysteine (NAC) on mortality reduction, with large effect sizes observed in meta-analyses of COVID-19 patients, rodenticide poisoning, and non-acetaminophen-induced acute liver injury. Three studies found no significant effect in different populations (esophageal atresia, acetaminophen overdose) or were narrative reviews. The predominant effect size is large, and the strongest evidence comes from critically ill clinical populations.
The study
- Meta-Analysis
- n = 424
- 2025-07-29
- Inflammopharmacology
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.